AR086984A1 - Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer - Google Patents
Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancerInfo
- Publication number
- AR086984A1 AR086984A1 ARP120102176A ARP120102176A AR086984A1 AR 086984 A1 AR086984 A1 AR 086984A1 AR P120102176 A ARP120102176 A AR P120102176A AR P120102176 A ARP120102176 A AR P120102176A AR 086984 A1 AR086984 A1 AR 086984A1
- Authority
- AR
- Argentina
- Prior art keywords
- cxcr4
- cancer treatment
- cxcr4 antibody
- chain variable
- variable domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente solicitud se refiere a un método para tratar el cáncer mediante la administración de un anticuerpo monoclonal anti-CXCR4 que tiene la capacidad de inducir una o más funciones efectoras.Reivindicación 1: Un anticuerpo humanizado que se une a CXCR4, o un fragmento de unión que contiene CH2 de éste; dicho anticuerpo humanizado comprende un dominio variable de la cadena pesada que se selecciona entre las secuencias SEQ ID Nº 7 a 10 y un dominio variable de la cadena ligera que se selecciona entre las secuencias SEQ ID Nº 11 a 17; para su empleo en un método del tratamiento del cáncer mediante la destrucción de una célula cancerígena que expresa CXCR4 mediante la inducción de, al menos, una función efectora, en la presencia de células efectoras o componentes del complemento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161499004P | 2011-06-20 | 2011-06-20 | |
EP11305773 | 2011-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR086984A1 true AR086984A1 (es) | 2014-02-05 |
Family
ID=44718440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102176A AR086984A1 (es) | 2011-06-20 | 2012-06-19 | Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer |
Country Status (13)
Country | Link |
---|---|
US (1) | US20140120555A1 (es) |
EP (1) | EP2721069A1 (es) |
JP (1) | JP6223966B2 (es) |
KR (1) | KR20140041698A (es) |
CN (1) | CN103649120A (es) |
AR (1) | AR086984A1 (es) |
AU (1) | AU2012274104B2 (es) |
BR (1) | BR112013032456A2 (es) |
CA (1) | CA2838484A1 (es) |
MA (1) | MA35173B1 (es) |
MX (1) | MX2013015061A (es) |
RU (1) | RU2013158624A (es) |
WO (1) | WO2012175576A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113683695A (zh) * | 2013-08-02 | 2021-11-23 | 辉瑞公司 | 抗cxcr4抗体及抗体-药物缀合物 |
TW201718851A (zh) * | 2015-09-18 | 2017-06-01 | 通用醫院公司 | 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途 |
US20180273897A1 (en) * | 2015-09-18 | 2018-09-27 | The General Hospital Corporation | Modified t-cells having anti-fugetactic properties and uses thereof |
BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
EP3765519B1 (en) * | 2018-03-13 | 2024-01-17 | Fundación para la Investigación Biomédica del Hospital Universitario la Paz | Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy |
US20210024873A1 (en) | 2018-03-27 | 2021-01-28 | Bristol-Myers Squibb Company | Real-time monitoring of protein concentration using ultraviolet signal |
WO2020172658A1 (en) | 2019-02-24 | 2020-08-27 | Bristol-Myers Squibb Company | Methods of isolating a protein |
WO2020237221A1 (en) | 2019-05-23 | 2020-11-26 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
KR20230080460A (ko) | 2020-10-05 | 2023-06-07 | 브리스톨-마이어스 스큅 컴퍼니 | 단백질을 농축시키는 방법 |
WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
RU2224766C2 (ru) | 1997-04-14 | 2004-02-27 | Микромет Аг | Способ получения рецепторов для человеческих антигенов и их применение |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
EP2264166B1 (en) * | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
ATE430580T1 (de) * | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
EP1921090B1 (en) | 2005-07-22 | 2015-01-14 | Kyowa Hakko Kirin Co., Ltd. | Genetically modified antibody composition |
EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
PL2066351T3 (pl) * | 2006-10-02 | 2016-02-29 | Squibb & Sons Llc | Przeciwciała ludzkie wiążące CXCR4 i ich wykorzystanie |
CN102027015A (zh) * | 2008-05-14 | 2011-04-20 | 伊莱利利公司 | 抗cxcr4抗体 |
EP2172485A1 (en) * | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
EP2371863A1 (en) * | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Humanized anti CXCR4 antibodies for the treatment of cancer |
-
2011
- 2011-06-20 US US14/126,944 patent/US20140120555A1/en not_active Abandoned
-
2012
- 2012-06-19 AR ARP120102176A patent/AR086984A1/es unknown
- 2012-06-20 JP JP2014516330A patent/JP6223966B2/ja not_active Expired - Fee Related
- 2012-06-20 KR KR1020147000453A patent/KR20140041698A/ko not_active Application Discontinuation
- 2012-06-20 EP EP12729573.1A patent/EP2721069A1/en not_active Withdrawn
- 2012-06-20 AU AU2012274104A patent/AU2012274104B2/en not_active Ceased
- 2012-06-20 BR BR112013032456A patent/BR112013032456A2/pt not_active IP Right Cessation
- 2012-06-20 CA CA2838484A patent/CA2838484A1/en not_active Abandoned
- 2012-06-20 WO PCT/EP2012/061893 patent/WO2012175576A1/en active Application Filing
- 2012-06-20 MX MX2013015061A patent/MX2013015061A/es not_active Application Discontinuation
- 2012-06-20 CN CN201280030414.8A patent/CN103649120A/zh active Pending
- 2012-06-20 RU RU2013158624/10A patent/RU2013158624A/ru not_active Application Discontinuation
-
2013
- 2013-12-10 MA MA36547A patent/MA35173B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
JP6223966B2 (ja) | 2017-11-01 |
US20140120555A1 (en) | 2014-05-01 |
MX2013015061A (es) | 2014-07-30 |
AU2012274104B2 (en) | 2017-06-15 |
BR112013032456A2 (pt) | 2016-11-22 |
CN103649120A (zh) | 2014-03-19 |
RU2013158624A (ru) | 2015-07-27 |
JP2014525899A (ja) | 2014-10-02 |
CA2838484A1 (en) | 2012-12-27 |
AU2012274104A1 (en) | 2014-01-09 |
EP2721069A1 (en) | 2014-04-23 |
MA35173B1 (fr) | 2014-06-02 |
WO2012175576A1 (en) | 2012-12-27 |
KR20140041698A (ko) | 2014-04-04 |
NZ618655A (en) | 2015-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR086984A1 (es) | Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer | |
ES2543174T3 (es) | Composición medicinal para el tratamiento y/o la prevención del cáncer | |
CL2016000324A1 (es) | Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1. | |
DOP2020000128A (es) | Anticuerpos anti-trem2 y métodos relacionados | |
AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
ES2584956T3 (es) | Anticuerpos anti-CD40 y usos de los mismos | |
PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
DOP2017000031A (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
PE20140673A1 (es) | Nuevos moduladores y metodos para su uso | |
AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
AR083293A1 (es) | Agentes de union a cd33 | |
ECSP17005649A (es) | Anticuerpos anti-tau humanizados | |
PE20190398A1 (es) | Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos | |
PE20130479A1 (es) | Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos | |
PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
AR068818A1 (es) | Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit | |
AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
AR102554A1 (es) | Receptores quiméricos de antígeno anti-cldn y métodos de uso | |
PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
CL2020002600A1 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |